TargetMol

Laquinimod

Product Code:
 
TAR-T6561
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6561-5mg5mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6561-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6561-10mg10mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6561-25mg25mg£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6561-50mg50mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6561-100mg100mg£191.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6561-500mg500mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Laquinimod is an effective immunomodulator, which is currently under development in phase III trials for the treatment of multiple sclerosis as an oral therapy.
CAS:
248281-84-7
Formula:
C19H17ClN2O3
Molecular Weight:
356.81
Pathway:
Apoptosis; ; NF-κb
Purity:
0.9884
SMILES:
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1
Target:
Apoptosis; NF-κB

References

Brunmark C, et al. J Neuroimmunol, 2002, 130(1-2), 163-172. Yang JS, et al. J Neuroimmunol, 2004, 156(1-2), 3-9. Gurevich M, et al. J Neuroimmunol, 2010, 221(1-2), 87-94. Zou LP, et al. Neuropharmacology, 2002, 42(5), 731-739. Runstr?m A, et al. J Neuroimmunol, 2006, 173(1-2), 69-78.